Publication:
The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung

dc.contributor.authorBakır, Kemal
dc.contributor.authorSivrikoz, Muammer Cumhur
dc.contributor.authorErbağcı, Burak
dc.contributor.authorUçak, Ramazan
dc.contributor.authorNurozler, Feza
dc.contributor.authorÜstünsoy, Haşim
dc.contributor.buuauthorŞenkaya, Işık
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentKardiyovasküler Cerrahi Ana Bilim Dalı
dc.contributor.scopusid15827259500tr_TR
dc.date.accessioned2021-11-30T13:09:25Z
dc.date.available2021-11-30T13:09:25Z
dc.date.issued2002-04
dc.description.abstractIn addition to preventing tissue energy loss during cardiopulmonary bypass. pentoxifylline (Ptx) prevents the production of pro-inflammatory cytokines as well. The aim of this study was to investigate whether Ptx decreases the inflammatory effects of cardiopulmonary bypass on the lungs during open-heart surgery, The patients in the study group (n=15) who were going through an open-heart surgery had 500 mg l(-1) of Ptx added to their prime solution, whereas the patients in the control group (n=10) only received prime solution. Pre-pump and post-pump blood samples were obtained from both groups and assayed for intereukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor alpha (TNFalpha), Lung tissue samples that were obtained after the pump were examined with light microscopy and stained for tissue TNFalpha Non-parametric Wilcoxon test was utilized for statistical evaluation, In the post-pump period, the difference in the IL-6, IL-8 and TNFalpha levels of the two groups was found to be statistically significant (P < 0.005). The tissue samples from the control group had significant staining with TNFalpha. We think that Ptx has important protective effects on the lungs during cardiopulmonary bypass.tr_TR
dc.identifier.citationÜstünsoy H. vd. (2002). "The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung". Respiratory Medicine, 96(4), 275-279.tr_TR
dc.identifier.endpage279tr_TR
dc.identifier.issn0954-6111
dc.identifier.issue4tr_TR
dc.identifier.pubmed12000008tr_TR
dc.identifier.scopus2-s2.0-0036553573tr_TR
dc.identifier.startpage275tr_TR
dc.identifier.urihttps://doi.org/10.1053/rmed.2001.1255
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0954611101912557
dc.identifier.urihttp://hdl.handle.net/11452/22893
dc.identifier.volume96tr_TR
dc.identifier.wos000175123200011
dc.indexed.pubmedPubmedtr_TR
dc.indexed.scopusScopustr_TR
dc.indexed.wosSCIEtr_TR
dc.language.isoentr_TR
dc.publisherW B Saunderstr_TR
dc.relation.collaborationYurtiçitr_TR
dc.relation.journalRespiratory Medicinetr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectPentoxifyllinetr_TR
dc.subjectLungtr_TR
dc.subjectInflammatory responsetr_TR
dc.subjectCardiopulmonary bypasstr_TR
dc.subjectMyocardial protectiontr_TR
dc.subjectIschemiatr_TR
dc.subjectReperfusiontr_TR
dc.subjectInjurytr_TR
dc.subjectCardiovascular system & cardiologytr_TR
dc.subjectRespiratory systemtr_TR
dc.subject.emtreeAdulttr_TR
dc.subject.emtreeAntiinflammatory activitytr_TR
dc.subject.emtreeArticletr_TR
dc.subject.emtreeBlood pumptr_TR
dc.subject.emtreeBlood samplingtr_TR
dc.subject.emtreeCardiopulmonary bypasstr_TR
dc.subject.emtreeChemoluminescencetr_TR
dc.subject.emtreeClinical articletr_TR
dc.subject.emtreeFemaletr_TR
dc.subject.emtreeClinical trialtr_TR
dc.subject.emtreeControlled clinical trialtr_TR
dc.subject.emtreeControlled studytr_TR
dc.subject.emtreeDrug mechanismtr_TR
dc.subject.emtreeHumantr_TR
dc.subject.emtreeHeart ventricle septum defecttr_TR
dc.subject.emtreeHistologytr_TR
dc.subject.emtreeHuman tissuetr_TR
dc.subject.emtreeImmunoassaytr_TR
dc.subject.emtreeMaletr_TR
dc.subject.emtreeLung biopsytr_TR
dc.subject.emtreeOpen heart surgerytr_TR
dc.subject.emtreePneumoniatr_TR
dc.subject.emtreePriority journaltr_TR
dc.subject.emtreeRank sum testtr_TR
dc.subject.emtreeStatistical significancetr_TR
dc.subject.emtreeValvular heart diseasetr_TR
dc.subject.emtreeAntibiotic agenttr_TR
dc.subject.emtreeBicarbonatetr_TR
dc.subject.emtreeCorticosteroidtr_TR
dc.subject.emtreeCytokinetr_TR
dc.subject.emtreeİnterleukin 6tr_TR
dc.subject.emtreeInterleukin 8tr_TR
dc.subject.emtreeMannitoltr_TR
dc.subject.emtreePentoxifyllinetr_TR
dc.subject.emtreeRinger lactate solutiontr_TR
dc.subject.emtreeTumor necrosis factor alphatr_TR
dc.subject.scopusPentoxifylline; Methylxanthine; Phosphodiesterase Inhibitorstr_TR
dc.subject.wosCardiac & cardiovascular systemstr_TR
dc.subject.wosRespiratory systemtr_TR
dc.titleThe inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lungtr_TR
dc.typeArticle
dc.wos.quartileQ2 (Cardiac & cardiovascular systems)tr_TR
dc.wos.quartileQ3 (Respiratory system)tr_TR
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Kardiyovasküler Cerrahi Ana Bilim Dalıtr_TR

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Şenkaya_vd_2002.pdf
Size:
236.52 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections